Various carrier system(s)- mediated genetic vaccination strategies against malaria.
The introduction of vaccine technology has facilitated an unprecedented multiantigen approach to develop an effective vaccine against complex pathogens, such as Plasmodium spp., that cause severe malaria. The capacity of multisubunit DNA vaccines encoding different stage Plasmodium antigens to induce CD8(+) cytotoxic T lymphocytes and IFN-gamma responses in mice, monkeys and humans has been observed. Moreover, genetic vaccination may be multi-immune (i.e., capable of eliciting more than one type of immune response, including cell-mediated and humoral). In the case of malaria parasites, a cytotoxic T-lymphocyte response is categorically needed against the intracellular hepatocyte stage while a humoral response, with antibodies targeted against antigens from all stages of the life cycle, is also needed. Therefore, the key to success for any DNA-based therapy is to design a vector able to serve as a safe and efficient delivery system. This has encouraged the development of nonviral DNA-mediated gene-transfer techniques, such as liposomes, virosomes, microspheres and nanoparticles. Efficient and relatively safe DNA transfection using lipoplexes makes them an appealing alternative to be explored for gene delivery. In addition, liposome-entrapped DNA has been shown to enhance the potency of DNA vaccines, possibly by facilitating uptake of the plasmid by antigen-presenting cells. Another recent technology using cationic lipids has been deployed and has generated substantial interest in this approach to gene transfer. This review comprises various aspects that could be decisive in the formulation of efficient and stable carrier system(s) for the development of malaria vaccines.
Tyagi
Rajeev K
RK
Biomedical Parasitology Unit, Pasteur Institute, 25-28 Rue Du Dr Roux, 75724 Paris Cedex 15, France. tyagi@pasteur.fr
Sharma
Pradeep Kumar
PK
Vyas
Suresh P
SP
Mehta
Abhinav
A
D006801:Humans; D008081:Liposomes / Q000276:immunology; D008288:Malaria / Q000276:immunology* / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000276:immunology*; D008863:Microspheres; D053758:Nanoparticles; D014611:Vaccination / Q000379:methods*; D019444:Vaccines, DNA / Q000276:immunology*; D022701:Virosomes / Q000276:immunology
D008081:Liposomes; D017780:Malaria Vaccines; D019444:Vaccines, DNA; D022701:Virosomes